Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SoftOx Solutions AS ( (DE:6FV) ) has provided an announcement.
SoftOx Solutions AS’s subsidiary, SoftOx Defense Solutions AS, has submitted a Phase 1 Clinical Trial Application to the Irish Health Products Regulatory Authority. This trial, part of the European Defense Fund program, aims to assess the safety and tolerability of the SoftOx Inhalation Solution as a medical countermeasure against biological warfare threats. The successful progress of this trial could enhance SoftOx’s strategic position in developing dual-use technologies, appealing to global pharmaceutical partners.
More about SoftOx Solutions AS
SoftOx Solutions AS is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo, developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The company collaborates with leading Nordic research institutes for its technology development.
YTD Price Performance: 421.43%
Average Trading Volume: 16,897,742
Current Market Cap: NOK172M
Learn more about 6FV stock on TipRanks’ Stock Analysis page.